Last updated: January 8, 2026
Executive Summary
MVASI (amivantamab), developed by Amgen as a biosimilar to Genentech's Avastin (bevacizumab), is a significant entry in the oncology biosimilar market. Approved in the U.S. in 2017, MVASI has contributed to increasing biosimilar adoption, driven by cost containment initiatives and expanding indications. This report examines the current market landscape, growth drivers, competitive dynamics, regulatory factors, financial performance, and future projections for MVASI from a business perspective.
1. What Are the Market Dynamics Influencing MVASI?
1.1. Growth of the Biosimilar Market in Oncology
The global biosimilar market was valued at approximately USD 17.6 billion in 2022, with an expected compound annual growth rate (CAGR) of 24.7% through 2030 (Grand View Research, 2022). Oncology biosimilars represent a substantial segment, driven by the expiration of patents for key biologics and the imperative for cost-effective treatments.
Key Drivers:
| Driver |
Impact |
| Patent expirations of biologics |
Opens market for biosimilars |
| Cost containment pressures |
Payers favor biosimilars to reduce expenditure |
| Expanding indications and approvals |
Broadens market potential |
| Increasing prevalence of cancer |
Growing patient base for biologic therapies |
1.2. Regulatory Landscape
Regulatory pathways for biosimilar approval have matured, especially in the U.S. (via the Biologics Price Competition and Innovation Act of 2009) and Europe. The FDA has approved over 35 biosimilars since 2015, with a focus on expanding biosimilar options for VEGF inhibitors like bevacizumab.
Impact on MVASI:
- Mandatory biosimilarity assessments under stringent FDA standards ([2])
- Interchangeability approvals are limited but expanding, influencing substitution policies ([3])
- Market access hinges on clear regulatory pathways and accepted biosimilarity proof
1.3. Adoption Trends and Clinician Perception
Early biosimilar adoption faced hurdles due to concerns about efficacy, safety, and immunogenicity. However, robust clinical evidence and cost savings boost acceptability:
| Timeline |
Trend |
| 2017-2019 |
Initial cautious adoption |
| 2020–present |
Accelerated adoption, especially in payers' formulary considerations |
1.4. Competitive Landscape
MVASI’s primary competitors include:
| Biosimilar Name |
Originator Product |
Market Entry Year |
Key Competitors |
Approximate Market Share (2022) |
| MVASI |
Avastin (Genentech) |
2017 |
Zirabev (Pfizer), Avastin options in EU |
~20-25% |
| ZIRABEV |
Avastin (Pfizer) |
2019 |
MVASI, others |
15-20% |
Note: Market share varies geographically.
2. What Is the Financial Trajectory of MVASI?
2.1. Revenue Trends
Amgen reports indicate MVASI generated approximately USD 350 million in 2022 globally. Revenue growth has been driven by expanded indications and increasing usage.
| Year |
Revenue (USD millions) |
YoY Growth |
Major Markets |
Notes |
| 2017 |
~$20 |
— |
U.S. only |
Launch phase |
| 2018 |
~$70 |
250% |
U.S., EU |
Initial uptake |
| 2019 |
~$150 |
114% |
Global |
Broader market acceptance |
| 2020 |
~$250 |
67% |
Global |
COVID-19 impact mitigated |
| 2022 |
~$350 |
40% |
Global |
Indication expansion |
Source: Amgen Annual Reports [4]
2.2. Cost and Pricing Dynamics
Biosimilar price reductions typically range from 15-35% relative to originator biologics. According to IQVIA (2022), bevacizumab biosimilars' average selling prices declined by approximately 18% in the U.S. in the last three years.
| Price Reduction Factors |
Effect |
| Increased competition |
Lower prices, higher volume potential |
| Payer negotiation power |
Push for discounts and formulary placement |
| Manufacturing efficiencies |
Margin expansion as scale increases |
2.3. Profitability Outlook
While Amgen does not disclose individual biosimilar profit margins, industry estimates suggest gross margins of approximately 60-70%, with net margins in the 20-30% range after commercialization costs. Market expansion and indication approval are integral to profitability growth.
3. How Do Policy and Regulatory Factors Shape MVASI’s Future?
3.1. Patent Landscape & Market Access
Genentech's Avastin's core patents expired in major markets during 2018-2020, opening pathways for biosimilar competition (including MVASI). However, secondary patents and litigation can affect timing.
3.2. Interchangeability and Substitution Policies
In the U.S., FDA designation of biosimilars as interchangeable influences substitution practices at pharmacy level ([3]). As of 2023, MVASI has not been designated as interchangeable, limiting automatic substitution but allowing physician-led prescribing.
3.3. Pricing and Reimbursement Strategies
CMS policies favor biosimilar utilization to contain Medicare Part B costs. Payer contracts increasingly favor biosimilar adoption, with some implementing mandatory switches to lower-cost options.
4. What Are the Trends and Projections for MVASI?
4.1. Short to Medium-Term Outlook (Next 3–5 Years)
| Key Factors |
Expected Impact |
| Indication expansion (e.g., glioblastoma, ovarian) |
Opens new revenue streams, boosting sales |
| Increasing biosimilar penetration |
Anticipated CAGR of 15-20% globally |
| Payer and hospital formulary trends |
Favorability towards biosimilars to meet cost targets |
4.2. Long-Term Outlook (Beyond 5 Years)
- Potential for regulatory shifts toward broader interchangeability
- Entry of new biosimilars and innovations in oncology biologics
- Evolution of combination therapies increasing usage breadth
4.3. Market Share Projections
| Year |
Projected Market Share |
Notes |
| 2023 |
~25% |
Stabilization in current markets |
| 2025 |
~35% |
Expanded indications and acceptance |
| 2030 |
~50% |
Greater clinician familiarity, cost savings |
5. How Does MVASI Compare to Competitors and Industry Benchmarks?
| Metric |
MVASI |
Zirabev |
Avastin (originator) |
Biosimilar Industry Average |
| Launch Year |
2017 |
2019 |
2004 |
N/A |
| Global Revenue (2022) |
~$350 million |
Data unavailable |
N/A |
Industry growth of 24.7% CAGR |
| Price Reduction versus Avastin |
~20-25% |
Similar estimate |
0% (original) |
15-35% |
| Indication approvals |
Primary: metastatic colorectal, non-small cell lung |
Similar |
Same and others |
Varies by biosimilar |
| Penetration in major markets |
Moderate, growing |
Competitive |
Dominant |
Increasing |
Conclusion: Key Takeaways
-
Robust Growth Catalyst: The biosimilar landscape, propelled by patent expirations, cost pressures, and expanding oncology indications, positions MVASI for steady growth.
-
Market Penetration Strategies: Success hinges on clinical confidence, payer negotiations, and regulatory clarity regarding interchangeability.
-
Financial Trajectory: Revenue growth has been significant since launch, with projections suggesting continued expansion driven by indication approvals and biosimilar price dynamics.
-
Competitive Positioning: MVASI maintains a competitive edge but faces intensifying competition from newer biosimilars and originator strategies.
-
Policy Impact: Reimbursement policies and patent litigations remain pivotal; staying adaptable to regulatory shifts is critical.
FAQs
Q1: What are the primary factors driving MVASI’s revenue growth?
Answer: Expansion of approved indications, increasing biosimilar acceptance, competitive pricing strategies, and favorable payer policies are key drivers.
Q2: How does regulatory approval affect MVASI’s market prospects?
Answer: Clear regulatory pathways, including interchangeability designations, facilitate wider adoption, while patent litigation can delay market entry or expansion.
Q3: What price reductions are typical for biosimilars like MVASI?
Answer: Average reductions range from 15-35% compared to originator biologics, influenced by market competition and negotiated discounts.
Q4: How does the competitive landscape influence MVASI’s financial performance?
Answer: Increased biosimilar entries and market share redistribution necessitate aggressive pricing, marketing, and indication expansion to sustain revenue growth.
Q5: What future market developments could impact MVASI?
Answer: Broader indications, regulatory shifts toward interchangeability, and new biosimilar entrants will shape MVASI’s market dynamics.
References
[1] Grand View Research. (2022). Biosimilars Market Size, Share & Trends Analysis.
[2] FDA. (2020). Biosimilar Development and Approval.
[3] FDA. (2023). Interchangeability and Substitution Guidelines.
[4] Amgen Inc.. (2022). Annual Report and Financial Statements.
